Illumina (ILMN) Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals

Simply Wall St.01-15

Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short term returns and longer term share price...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603046649?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-01-15 00:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603046649","market":"sg","top_or_hot":-1,"title":"Illumina (ILMN) Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals","media":"Simply Wall St.","content":"<div>\n<p>Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short term returns and longer term share price...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-recent-share-price-rebou\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina (ILMN) Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina (ILMN) Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 00:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-recent-share-price-rebou><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short term returns and longer term share price...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-recent-share-price-rebou\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-recent-share-price-rebou","article_id":"2603046649","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-recent-share-price-rebou","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603046649","pubTimestamp":1768407577,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short term returns and longer term share price pressure.\nSee our latest analysis for Illumina.\nThe recent 1 day share price return of 0.99% and 30 day share price return of 8.99% sit alongside a 90 day share price return of 58.05%. However, the 5 year total shareholder return of 61.24% and 3 year total shareholder return of 26.73% highlight...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4548":"巴美列捷福持仓","BK4588":"碎股","BK4534":"瑞士信贷持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","ILMN":"Illumina","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念"},"translate_title":"Illumina(ILMN)在近期股价反弹和公允价值信号相互矛盾后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"ILMN":1.5},"content_text":"Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short term returns and longer term share price pressure. See our latest analysis for Illumina. The recent 1 day share price return of 0.99% and 30 day share price return of 8.99% sit alongside a 90 day share price return of 58.05%. However, the 5 year total shareholder return of 61.24% and 3 year total shareholder return of 26.73% highlight that longer term holders have still experienced significant value erosion. If Illumina’s latest move has caught your attention, it could be a useful moment to compare it with other healthcare names using healthcare stocks. With Illumina trading at US$146.99, a discount to one intrinsic value estimate and above some external targets, the key question is simple: is the stock still undervalued here, or already pricing in future growth? AdvertisementMost Popular Narrative: 22.7% Overvalued Illumina’s fair value in the most followed narrative sits at US$119.84, below the last close of US$146.99. This frames the current debate around pricing.  Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, creates incremental growth opportunities by increasing the breadth of Illumina's data and platform offerings, contributing to future revenue and operating margin expansion.  Read the complete narrative. Want to see what kind of revenue path and margin profile could justify that higher valuation bar? The narrative leans on measured top line growth, margin compression, and a richer earnings multiple that still sits below many life sciences peers. Curious how those ingredients fit together into that US$119.84 fair value? Result: Fair Value of $119.84 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still key pressure points, including ongoing export restrictions and approvals in China, as well as rising competition that could weigh on revenue and margins if conditions worsen. Find out about the key risks to this Illumina narrative. Another View: DCF Points the Other Way The most followed narrative tags Illumina as about 22.7% overvalued at US$146.99 versus a US$119.84 fair value. Our DCF model lands in a very different place, with a fair value estimate of US$180.64, which puts the current price roughly 18.6% below that mark. Which story do you think fits the business better? Look into how the SWS DCF model arrives at its fair value. ILMN Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 884 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Illumina Narrative If you look at the numbers and come to a different conclusion, or simply prefer to test your own assumptions, you can build a custom thesis in a few minutes using Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Illumina. Looking for more investment ideas? If Illumina has you thinking harder about your portfolio, do not stop here. The next step is lining up a few fresh ideas to compare.  Target potential value opportunities by scanning these 884 undervalued stocks based on cash flows that may be trading below what their cash flows imply. Consider the growth of artificial intelligence by checking out these 25 AI penny stocks that are directly tied to this theme. Adjust your income focus by reviewing these 13 dividend stocks with yields > 3% that already offer yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603046649","isCrawlerRequest":true}